1. Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B)
*Participants who received drug in period 1 received placebo in period 2 and vice versa
Rajesh Krishna, et al. Lancet 2007;370:

2. Change from baseline versus time profiles for serum HDL-C (A), LDL-C (B), apolipoprotein A-I (C), and apolipoprotein B (D) after administration of anacetrapib or placebo to patients with dyslipidaemia
Rajesh Krishna, et al. Lancet 2007;370:

3. Hourly mean systolic (A) and diastolic (B) blood pressure (SE) over 24 h post-dose on day 10 after administration of anacetrapib (or matching placebo) in healthy middle-aged and elderly people (N=22)
R. Krishna, et al. Lancet 2007;370:

4. Mean ambulatory systolic and diastolic blood pressure at 24 h post-dose on day 10 after administration of anacetrapib or placebo in healthy middle-aged and elderly people (N=22)
Rajesh Krishna, et al. Lancet 2007;370:

5. Incidence of adverse events in patients with dyslipidaemia
Rajesh Krishna, et al. Lancet 2007;370:

6. Incidence of adverse events in ambulatory blood pressure study
Rajesh Krishna, et al. Lancet 2007;370: